Low levels of anti-cyclic citrullinated peptide (CCP) 3.1 associated with diseases other than rheumatoid arthritis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
23 Apr 2021
23 Apr 2021
Historique:
received:
08
07
2020
accepted:
29
03
2021
entrez:
21
4
2021
pubmed:
22
4
2021
medline:
27
4
2021
Statut:
ppublish
Résumé
Our aim was to investigate the newest generation anti-cyclic citrullinated peptide (CCP) antibody 3.1 assay in diagnosing rheumatoid arthritis (RA) compared with other autoimmune and non-autoimmune diseases. We performed a retrospective observational chart review of patients with a positive CCP level over a one-year period at a single academic institution and assessed the associated diagnoses after at least six-months of follow-up. Of the 281 CCP positive patients during that period, 48% had a diagnosis of RA. The positive predictive value of RA in patients with a high CCP 3.1 assay was 0.619 compared to 0.248 with a low positive CCP 3.1 assay (P < .0001). Overall, there was a lower than expected positive predictive value of CCP 3.1 level with an RA diagnosis, though the likelihood of having an RA diagnosis was higher with a higher CCP level.
Identifiants
pubmed: 33879708
doi: 10.1097/MD.0000000000025558
pii: 00005792-202104230-00055
pmc: PMC8078438
doi:
Substances chimiques
Autoantibodies
0
Peptides, Cyclic
0
cyclic citrullinated peptide
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25558Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
No conflicts of interest or funding disclosures to report.
Références
Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005;4:130–6.
Van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 2011;7:391–8.
Demoruelle MK, Parish MC, Derber LA, et al. Performance of anti-cyclic citrullinated peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease. Arthritis Rheum 2013;65:2243–52.
Szekanecz Z, Szabó Z, Zeher M, et al. Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population. Immunol Res 2013;56:439–43.
Dos Anjos LM, Pereira IA, d ’Orsi E, et al. A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis. Clin Rheumatol 2009;28:153–8.
Bizzaro N, Tonutti E, Tozzoli R, et al. Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem 2007;53:1527–33.
Webb T, Lakos G, Swart A, et al. Clinical evaluation of a novel chemiluminescent immunoassay for the detection of anti-citrullinated peptide antibodies. Clin Chim Acta 2014;437:161–7.
Innala L, Kokkonen H, Eriksson C, et al. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008;35:1002–8.
Infantino M, Manfredi M, Meacci F, et al. Anti-citrullinated peptide antibodies and rheumatoid factor isotypes in the diagnosis of rheumatoid arthritis: an assessment of combined tests. Clin Chim Acta 2014;436:237–42.
Damjanovska L, Thabet MM, Levarth EW, et al. Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis. Ann Rheum Dis 2010;69:730–2.
Bizzaro N, Tampoia M. Diagnostic accuracy of immunoassays for the detection of antibodies to citrullinated proteins. Clin Rev Allergy Immunol 2008;34:16–20.
Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003;62:870–4.
Van Noord C, Hooijkaas H, Dufour-van den Goorbergh BC, et al. Diagnostic value of anti-cyclic citrullinated peptide antibodies to detect rheumatoid arthritis in patients with Sjögren's syndrome. Ann Rheum Dis 2005;64:160–2.
Kokkonen H, Mullazehi M, Berglin E, et al. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis. Arthritis Res Ther 2011;13:R13.
Berens HM, Polinski KJ, Mikuls TR, et al. Anti-CCP3.1 and Anti-CCP-IgA are associated with increasing age in individuals without rheumatoid arthritis. J Rheumatol 2019;46:1556–9.